Climb Bio's CLYM116 Data Could Show Competitive Position in IgA Nephropathy Market, Oppenheimer Says

MT Newswires Live09-03

Climb Bio's (CLYM) CLYM116 could stand out in the growing IgA nephropathy treatment market if Thursday's phase 1 data shows strong and lasting APRIL and IgA reductions that support less frequent dosing, Oppenheimer said in a note Wednesday.

The key question for Thursday's results is whether CLYM116 can deliver strong and durable effects that could support an infrequently administered under-the-skin treatment, Oppenheimer said.

The investment firm said other approved and experimental anti-APRIL drugs have already shown that targeting APRIL can work in IgAN, setting a benchmark for CLYM116.

The phase 2 portion of partner Mabworks' phase 1/2 IgAN study is expected to begin before the end of the quarter, with Climb Bio planning to present additional CLYM116 data at a medical meeting in Q4, the firm noted.

Oppenheimer kept its outperform rating and $18 price target for Climb Bio.

Price: 14.62, Change: -0.21, Percent Change: -1.38

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2664756848?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-03 00:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664756848","market":"fut","top_or_hot":-1,"title":"Climb Bio's CLYM116 Data Could Show Competitive Position in IgA Nephropathy Market, Oppenheimer Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CLYM\">Climb Bio</a>'s (CLYM) CLYM116 could stand out in the growing IgA nephropathy treatment market if Thursday's phase 1 data shows strong and lasting APRIL and IgA reductions that support less frequent dosing, Oppenheimer said in a note Wednesday.</p><p>The key question for Thursday's results is whether CLYM116 can deliver strong and durable effects that could support an infrequently administered under-the-skin treatment, Oppenheimer said.</p><p>The investment firm said other approved and experimental anti-APRIL drugs have already shown that targeting APRIL can work in IgAN, setting a benchmark for CLYM116.</p><p>The phase 2 portion of partner Mabworks' phase 1/2 IgAN study is expected to begin before the end of the quarter, with Climb Bio planning to present additional CLYM116 data at a medical meeting in Q4, the firm noted.</p><p>Oppenheimer kept its outperform rating and $18 price target for Climb Bio.</p><p>Price: 14.62, Change: -0.21, Percent Change: -1.38</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Climb Bio's CLYM116 Data Could Show Competitive Position in IgA Nephropathy Market, Oppenheimer Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClimb Bio's CLYM116 Data Could Show Competitive Position in IgA Nephropathy Market, Oppenheimer Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-03 00:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CLYM\">Climb Bio</a>'s (CLYM) CLYM116 could stand out in the growing IgA nephropathy treatment market if Thursday's phase 1 data shows strong and lasting APRIL and IgA reductions that support less frequent dosing, Oppenheimer said in a note Wednesday.</p><p>The key question for Thursday's results is whether CLYM116 can deliver strong and durable effects that could support an infrequently administered under-the-skin treatment, Oppenheimer said.</p><p>The investment firm said other approved and experimental anti-APRIL drugs have already shown that targeting APRIL can work in IgAN, setting a benchmark for CLYM116.</p><p>The phase 2 portion of partner Mabworks' phase 1/2 IgAN study is expected to begin before the end of the quarter, with Climb Bio planning to present additional CLYM116 data at a medical meeting in Q4, the firm noted.</p><p>Oppenheimer kept its outperform rating and $18 price target for Climb Bio.</p><p>Price: 14.62, Change: -0.21, Percent Change: -1.38</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLYM","symbol_name":"CLIMB BIO INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2664756848","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664756848","pubTimestamp":1788365551,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Climb Bio's  CLYM116 could stand out in the growing IgA nephropathy treatment market if Thursday's phase 1 data shows strong and lasting APRIL and IgA reductions that support less frequent dosing, Oppenheimer said in a note Wednesday.The key question for Thursday's results is whether CLYM116 can deliver strong and durable effects that could support an infrequently administered under-the-skin treatment, Oppenheimer said.The investment firm said other approved and experimental anti-APRIL drugs have already shown that targeting APRIL can work in IgAN, setting a benchmark for CLYM116.The phase 2 portion of partner Mabworks' phase 1/2 IgAN study is expected to begin before the end of the quarter, with Climb Bio planning to present additional CLYM116 data at a medical meeting in Q4, the firm noted.Oppenheimer kept its outperform rating and $18 price target for Climb Bio.Price: 14.62, Change: -0.21, Percent Change: -1.38","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLYM":"CLIMB BIO INC","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"Oppenheimer 表示，Climb Bio 的 CLYM116 数据可能显示其在 IgA 肾病市场的竞争地位","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLYM":1},"content_text":"Climb Bio's (CLYM) CLYM116 could stand out in the growing IgA nephropathy treatment market if Thursday's phase 1 data shows strong and lasting APRIL and IgA reductions that support less frequent dosing, Oppenheimer said in a note Wednesday.The key question for Thursday's results is whether CLYM116 can deliver strong and durable effects that could support an infrequently administered under-the-skin treatment, Oppenheimer said.The investment firm said other approved and experimental anti-APRIL drugs have already shown that targeting APRIL can work in IgAN, setting a benchmark for CLYM116.The phase 2 portion of partner Mabworks' phase 1/2 IgAN study is expected to begin before the end of the quarter, with Climb Bio planning to present additional CLYM116 data at a medical meeting in Q4, the firm noted.Oppenheimer kept its outperform rating and $18 price target for Climb Bio.Price: 14.62, Change: -0.21, Percent Change: -1.38","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2664756848","isCrawlerRequest":true}